Low-dose natural human interferon-? lozenges in the treatment of Behcet's syndrome

Basit Öğe Kaydı
dc.authoridGul, Ahmet/0000-0001-8219-3720
dc.authorwosidGul, Ahmet/AAT-7787-2020
dc.contributor.authorKilic, Hasan
dc.contributor.authorZeytin, Hasan E.
dc.contributor.authorKorkmaz, Cengiz
dc.contributor.authorMat, Cem
dc.contributor.authorGul, Ahmet
dc.contributor.authorCosan, Fulya
dc.contributor.authorDinc, Ayhan
dc.date.accessioned2024-06-12T10:54:21Z
dc.date.available2024-06-12T10:54:21Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives. There had been evidence that low-dose local IFN could be beneficial in the management of recurrent oral ulcers (OUs). We investigated the efficacy and collected initial data on the safety of low-dose natural human IFN-alpha administered by the oral mucosal route in Behcet's syndrome (BS) in a placebo controlled, double blind study. Methods. Eighty-four (59 males and 25 females) patients with BS with mainly skin mucosa disease and a history of recurrent OU for >= 1 year were studied. When they had at least two OUs with a total diameter of >= 4mm, they were randomly allocated to (i) 2000 IFN-alpha IU/day, (ii) 1000 IFN-alpha IU/day and (iii) placebo groups. Subjects were monitored weekly over an initial 4 weeks and bi-weekly for an additional 8 weeks of treatment. OU were counted and measured at each study visit. The primary efficacy end point was the difference in the total ulcer burden at Week 0 compared with that at Week 12. Results. Out of the 84 patients enrolled, 72 completed the trial. There were no statistically significant differences between the treatment arms in terms of the primary endpoint. Conclusions. Low-dose natural human IFN-alpha did not have beneficial effects on reducing the total ulcer burden among BS patients from Turkey. The study also showed that counting the number of ulcers rather than measuring the size would be adequate in future studies.en_US
dc.description.sponsorshipNobel Ilac San. ve Tic. A.S., Istanbul, Turkeyen_US
dc.description.sponsorshipThis work was supported by Nobel Ilac San. ve Tic. A.S., Istanbul, Turkey.en_US
dc.identifier.doi10.1093/rheumatology/kep237
dc.identifier.endpage1391en_US
dc.identifier.issn1462-0324
dc.identifier.issn1462-0332
dc.identifier.issue11en_US
dc.identifier.pmid19717547en_US
dc.identifier.startpage1388en_US
dc.identifier.urihttps://doi.org/10.1093/rheumatology/kep237
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19016
dc.identifier.volume48en_US
dc.identifier.wosWOS:000271577700012en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofRheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBehcet's Syndromeen_US
dc.subjectOral Ulcersen_US
dc.subjectLow-Dose Oral Interferon-Alphaen_US
dc.subjectSjogrens-Syndromeen_US
dc.subjectDiseaseen_US
dc.subjectTrialen_US
dc.titleLow-dose natural human interferon-? lozenges in the treatment of Behcet's syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu